Electra Therapeutics (ETRA) Q3 2026 earnings summary

Executive summary

• Q3 net loss was $23.9M; 9M net loss was $72.840M vs. $43.453M in 2025. No product revenue has been generated to date.

• Quarter-end cash, cash equivalents and marketable securities totaled $402.5M; the current operating plan is expected to be funded into 2029.

• Ipsoprubart is advancing in a registrational sHLH program, with enrollment completion expected in H2 2027; ELA822 began a Phase 1 healthy-volunteer trial, with initial data expected in H1 2027.

• A $350M IPO was completed in September 2026 to advance the SIRP-targeting portfolio.

Financial highlights

• Q3 operating expenses were $25.1M, up 47% YoY; 9M expenses were $75.291M vs. $42.391M in 2025.

• Q3 R&D was $17.3M, up 16% YoY; 9M R&D was $58.9M, driven by ipsoprubart and ELA822 development.

• Q3 G&A was $7.8M vs. $2.1M; 9M G&A was $16.4M vs. $8.7M, reflecting IPO-related stock compensation, headcount and professional fees.

• Q3 interest income rose to $1.1M from $0.2M; 9M interest income increased to $2.5M from $0.6M.

Outlook and guidance

• Quarter-end cash and securities are expected to fund the current operating plan into 2029, subject to development and regulatory uncertainties.

• ELA822 healthy-volunteer data are expected in H1 2027; a first-in-disease patient trial is planned for mid-2027, subject to regulatory approval.

• Ipsoprubart registrational-program enrollment completion and initial data in T/NK malignancies are expected in H2 2027.

• Operating losses and R&D expenses are expected to increase substantially as clinical programs advance, pipeline work expands and public-company costs grow.